# Project REAL FIB: atrial fibrillation in real Praxis register

Submission date	Recruitment status	Prospectively registered
09/03/2010	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
06/04/2010	Completed	Results
Last Edited	Condition category	Individual participant data
06/04/2010	Circulatory System	Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Prof Robert Hatala

#### Contact details

Národný ústav srdcových a cievnych chorôb Pod Krásnou hôrkou 1 Bratislava 37 Slovakia 833 48 hatala@nusch.sk

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

# Secondary identifying numbers

2009, protocol version 6.0, 18.01.2010

# Study information

#### Scientific Title

Project REAL FIB - atrial fibrillation in real Praxis register: a multicentre, non-interventional, observational and prospective study

#### Acronym

**REAL FIB** 

#### **Study objectives**

Charting of therapeutic methods indicated by medical doctors of different specialisations (cardiologists, internists) in prevention of atrial fibrillation from all over the country.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Multicentric Ethics Committee approved on the 21st December 2009 (ref: 108728/2009-11)

#### Study design

Multicentre non-interventional observational prospective cohort study

#### Primary study design

Observational

#### Secondary study design

Cohort study

# Study setting(s)

Other

# Study type(s)

Diagnostic

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

# Health condition(s) or problem(s) studied

Atrial fibrillation (AF)

#### **Interventions**

This is a non-interventional study, all interventions will be performed according to common clinical Praxis in the management and follow up of patients with atrial fibrillation on treatment.

#### Baseline visit:

- 1. Demographic data collection
- 2. Risk factors assessment: height, weight, age, patient history (hypertension, age when AF diagnosed, coronary disease, heart failure, New York Heart Association [NYHA] classification, systolic dysfunction, ejection fraction, diastolic dysfunction, sick sinus syndrome, cardiostimulator, implantable cardioverter-defibrillator [ICD], history of cardiovascular surgery, other heart diseases, mitral valve disease and type, diabetes mellitus), blood sugar level, dyslipidaemia, cholesterol level, low density lipoprotein [LDL]-cholesterol level, chronic renal

insufficiency, creatinine, urea, ions, thyreopathy, body mass index [BMI], transient ischaemic attack [TIA]/cerebrovascular accident [CVA], alcohol abuse, family history for AF, CHADS score 3. AF characteristics

4. Treatment strategy (rhythm control, frequency control, thrombembolism prevention, other treatment)

#### Follow up (6 months):

- 1. Basic data
- 2. Accidental events
- 3. Treatment strategy

#### Follow up (12 months):

- 1. Basic data
- 2. Accidental events
- 3. Treatment strategy

#### Intervention Type

Other

#### Phase

Not Applicable

#### Primary outcome measure

- 1. To assess clinical profile of patients with atrial fibrillation
- 2. To assess contemporary treatment modalities and its effectiveness
- 3. To observe occurence of cardiovascular events prospectively

#### Secondary outcome measures

1. To analyse correlation between treatment modalities indicated by medical doctors of different specialisations (cardiologists, internists) in prevention of atrial fibrillation 2. To collect treatment safety data

#### Overall study start date

01/02/2010

#### Completion date

30/04/2011

# **Eligibility**

#### Key inclusion criteria

All patients diagnosed with atrial fibrillation (any age, either sex)

#### Participant type(s)

Patient

#### Age group

Other

#### Sex

#### Both

# Target number of participants

1000

## Key exclusion criteria

Does not meet inclusion criteria

#### Date of first enrolment

01/02/2010

#### Date of final enrolment

30/04/2011

# Locations

#### Countries of recruitment

Slovakia

#### Study participating centre Národný ústav srdcových a cievnych chorôb

Bratislava 37 Slovakia 833 48

# Sponsor information

#### Organisation

Masaryk University (Czech Republic)

#### Sponsor details

c/o Doc. RNDr. Ladislav Duek, Ph.D.
Institute of Biostatistics and Analyses
Faculty of Medicine and the Faculty of Science
Kamenice 2
Brno-Bohunice
Czech Republic
625 00
dusek@iba.muni.cz

## Sponsor type

University/education

#### Website

http://www.muni.cz/

#### ROR

https://ror.org/02j46qs45

# Funder(s)

# Funder type

University/education

#### **Funder Name**

Masaryk University (Czech Republic) - Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration